Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Foralumab alone or in combination with dexamethasone for treatment of COVID-19 patients

Next Previous
X
Search
Trial Profile

A clinical study of Foralumab alone or in combination with dexamethasone for treatment of COVID-19 patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Foralumab (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Aug 2021 According to a Tiziana Life Sciences media release, results published in the peer-reviewed journal Frontiers in Immunology.
    • 17 Aug 2021 Results presented in a Tiziana Life Sciences Media Release.
    • 26 Feb 2021 According to a Tiziana Life Sciences media release, an interview with CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on February 27, 2021. Topline data from this study will be discussed in the exclusive interview.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top